Federal Register - September 13, 2021
Versión en texto ¿Qué es?Dateas es un sitio independiente no afiliado a entidades gubernamentales. La fuente de los documentos PDF aquí publicados es la entidad gubernamental indicada en cada uno de ellos. Las versiones en texto son transcripciones no oficiales que realizamos para facilitar el acceso y la búsqueda de información, pero pueden contener errores o no estar completas.
Fuente: Federal Register
50898
Federal Register / Vol. 86, No. 174 / Monday, September 13, 2021 / Notices
Jane M. Lambert, Project Clearance Liaison, National Institute of Environmental Health Sciences, National Institutes of Health.
FR Doc. 202119693 Filed 91021; 8:45 am BILLING CODE 414001P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Athenex, Inc.
Athenex headquartered in Buffalo, NY.
SUMMARY:
Only written comments and/or applications for a license which are received by the National Cancer Institutes Technology Transfer Center on or before September 28, 2021 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Suna Gulay French, Ph.D., Technology Transfer Manager, NCI
Technology Transfer Center, Telephone:
2402765530; Email: suna.gulay@
nih.gov.
DATES:
SUPPLEMENTARY INFORMATION:
Intellectual Property GROUP A:
lotter on DSK11XQN23PROD with NOTICES1
E23720170/2: T Cell Receptors Recognizing Mutated P53
1. US Provisional Patent Application 62/565,383, filed September 29, 2017
E23720170US01;
2. International Patent Application PCT/US2018/051285, filed September 17, 2018 E23720172PCT01;
3. Australian Patent Application 2018342246, filed September 17, 2018
E23720172AU02;
4. Brazilian Patent Application BR1120200060127, filed September 17, 2018 E23720172BR03;
VerDate Sep<11>2014
17:39 Sep 10, 2021
Jkt 253001
5. Canadian Patent Application 3977024, filed September 17, 2018 E
23720172CA04;
6. Chinese Patent Application 201880074539.8, filed September 17, 2018 E23720172CN05;
7. Costa Rica Patent Application 20200170, filed September 17, 2018
E23720172CR06;
8. Eurasian Patent Application 202090757, filed September 17, 2018
E23720172EA07;
9. European Patent Application 18780006.5, filed September 17, 2018
E23720172EP08;
10. Israeli Patent Application 273515, filed September 17, 2018 E2372017
2IL09;
11. India Patent Application 202047013911, filed September 17, 2018
E23720172IN10;
12. Japanese Patent Application 2020
517556, filed September 17, 2018 E
23720172JP11;
13. Korean Patent Application 2020
7012344, filed September 17, 2018 E
23720172KR12;
14. Mexico Patent Application MX/a/
2020/003504, filed September 17, 2018
E23720172MX13;
15. New Zealand Patent Application 763023, filed September 17, 2018 E
23720172NZ14;
16. Singapore Patent Application 11202002636P, filed September 17, 2018 E23720172SG15;
17. United States Utility Patent Application 16/651,242, filed September 17, 2018 E23720172
US16; and 18. Hong Kong Patent Application 62020021272.3, filed November 30, 2020 E23720172HK17.
E1352019: T Cell Receptors Recognizing R175H or Y220C Mutation in P53
1. US Provisional Patent Application 62/867,619, filed June 27, 2019 E135
20190US01;
2. International Patent Application PCT/US2020/039785, filed June 26, 2020 E13520190PCT02; and 3. Taiwanese Patent Application 109121744, filed June 26, 2020 E135
20190TW03.
E1732020: T Cell Receptors Recognizing R273C or Y220C Mutation in P53
1. US Provisional Patent Application 63/074,747, filed September 4, 2020 E
17320200US01.
E0982018: T Cell Receptors Which Recognize Mutated EGFR
1. US Provisional Patent Application 62/665,234, filed May 1, 2018 E098
20180US01;
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
2. International Patent Application PCT/US2019/030108, filed May 1, 2019
E09820180PCT02;
3. Australian Patent Application 2019263233, filed May 1, 2019 E098
20180AU03;
4. Canadian Patent Application 3,099,106, filed May 1, 2019 E098
20180CA04;
5. European Patent Application 19723615.1, filed May 1, 2019 E098
20180EP05; and 6. United States Utility Patent Application 17/051,860, filed May 1, 2019 E09820180US06.
E1652020: HLA Class II-Restricted DRB T Cell Receptors Against RAS With G12D Mutation 1. US Provisional Application 63/
050,9131, filed July 13, 2020 E165
20200US01; and 2. International Patent Application PCT/US2021/041375, filed July 13, 2021
E16520200PCT02.
E1722020: HLA Class II-Restricted DRB T Cell Receptors Against RAS With G12V Mutation 1. US Provisional Application 63/
052,502, filed July 16, 2020 E172
20200US01; and 2. International Patent Application PCT/US2021/041737, filed July 15, 2021
E17220200PCT02.
E1892020: HLA Class II-Restricted DQ
T Cell Receptors Against RAS With G13D Mutation 1. US Provisional Application 63/
086,674, filed October 2, 2020 E189
20200US01.
E1902020: HLA Class I-Restricted T
Cell Receptors Against RAS With G12V
Mutation 1. US Provisional Application 63/
060,340, filed August 3, 2020 E190
20200US01 and U.S., PCT and foreign patent applications claiming priority to the aforementioned application.
GROUP B:
E23720171: Methods of Isolating T
Cells Having Antigenic Specificity for a P53 Cancer-Specific Mutation 1. US Provisional Patent Application 62/565,464, filed September 29, 2017
E23720171US01;
2. International Patent Application PCT/US2018/051280, filed September 17, 2018 E23720171PCT02;
3. Australian Patent Application 2018342245, filed September 17, 2018
E23720171AU03;
4. Canadian Patent Application 3080274, filed September 17, 2018 E
23720171CA04;
E:FRFM13SEN1.SGM
13SEN1
